Welcoem to posts!!
in the future - u will be able to do some more stuff here,,,!! like pat catgirl- i mean um yeah... for now u can only see others's posts :c
Have you gotten your updated holy trinity of vaccines yet? We've teamed up with the @CDC to create educational videos about immunization recommendations for the fall and winter virus season. Whether you're a healthcare provider, patient, or caregiver, make a positive impact on community health by staying informed and being up-to-date on vaccines for flu, COVID-19, and RSV to safeguard public health!
Watch our free video series on vaccinations here: osms.it/cdc-vax-playlist-sm
38 - 1
Today we're sharing another practice question similar to one you may find on the NCLEX-RN® to test your knowledge of nursing topics.
The nurse in the genealogy clinic is working with a patient who has tested positive for the HTT gene which causes Huntington disease. The patient states that they do not want their results shared with their significant other.
Which ethically complex issue does this situation directly relate to?
Comment your answer, then check to see if you got it correct: osms.it/qotd-nclex-htt-gene-yt
Learn more about the code of ethics on Osmosis from Elsevier: osms.it/qotd-nclex-coe-htt-gene-yt
181 - 4
This week, we're sharing another USMLE® Step 1-style practice question to test your knowledge of medical topics.
Today's question revolves around a 28-year-old Gravida 1 para 0 woman presenting to the emergency department due to severe abdominal pain and jaundice. The patient's symptoms started one week ago after returning from a trip to Southeast Asia. The patient’s partner had mild fatigue and jaundice but is currently improving.
Initial bloodwork from the patient shows markedly elevated bilirubin and transaminases. The patient is admitted to the intensive care unit but eventually develops fulminant liver failure and dies. Autopsy shows patchy necrosis of the liver, and the cause of liver damage is determined to be viral hepatitis.
The virus causing this patient’s hepatitis most likely belongs to which of the following viral families?
Comment your answer, then check to see if you got it correct: osms.it/qotd-step1-viral-hepatitis-yt
Learn more about the diagnosis on Osmosis from Elsevier: osms.it/qotd-step1-dx-viral-hepatitis-yt
Ready for a Step 2 CK question? Explore the new Osmosis Clinical Sciences library! Our visually engaging videos, decision-making trees, and linked board-style assessments help you develop your clinical practice skills and ace your exams.
293 - 15
We're grateful for the time we've shared in the past, but can we have a little more? 🥺 Come back and explore all of our updates for FREE! Simply log back into your account, and we'll add a free week of Osmosis Suite for you to check out the new videos, questions, decision-making trees, case studies, and other goodies we've put out since you've been gone.
Promotion ends Friday (11/22) at midnight PST.
129 - 1
Happy #Movember! We're here to counter the perceived stigma surrounding conversations about men's reproductive health conditions. In this week's Osmosis from Elsevier blog, familiarize yourself with common men's reproductive health disorders and their signs, symptoms, diagnoses, and treatment options: osms.it/blog-male-reproductive-health-yt
340 - 2
Get back to the (heart)beat with today's #MedsYouShouldKnow: flecainide!
Flecainide is a class I antiarrhythmic, also known as a sodium channel blocker. It's used for treating a variety of cardiac arrhythmias, such as atrial fibrillation, supraventricular arrhythmias, and some ventricular arrhythmias.
This drug works by blocking sodium influx, which affects conduction and/or repolarization in the cardiac conduction system to reduce and stabilize arrythmias.
Route of administration: PO
Common side effects:
• Dizziness
• New arrhythmias
• Bradycardia
• Hypotension
• Gastrointestinal disturbances
Contraindications: patients with pre-existing hypotension, heart failure, bradycardia, heart block, or torsades de pointes.
Black box warning: if patients have had a myocardial infarction (MI) within the past two years, flecainide may increase risk of having another MI.
Learn more about flecainide and other antiarrhythmics: osms.it/mysk-flecainide-yt
Try Osmosis from Elsevier for free: osms.it/free-trial-nov24-yt
103 - 0
Hey, we've missed you... 👉👈 So come back and explore all of our updates for FREE! Simply log back into your account, and we'll add a free week of Osmosis Suite for you to check out the new videos, questions, decision-making trees, case studies, and other goodies we've put out since you've been gone.
Promotion ends November 22nd at midnight PST.
169 - 6
Try saying "nephrolithiasis" three times fast! Today's #DecisionTreeBranch reviews the clinical approach to nephrolithiasis.
Nephrolithiasis, also known as renal calculi or renal stones, is a painful condition where crystals form in the kidney, potentially causing urinary tract obstruction. Renal stones usually form when urine becomes oversaturated with minerals and salts, including calcium, oxalate, and uric acid.
If your patient presents with a chief concern suggesting nephrolithiasis, you should first perform an ABCDE assessment to determine if your patient is unstable or stable. If your patient is stable, obtain a focused history and physical examination and order a urinalysis.
Patients with nephrolithiasis typically present with an acute onset of excruciating flank pain, along with hematuria. They may also experience dysuria, nausea, or vomiting.
The physical examination usually reveals unilateral flank tenderness, and urinalysis can show red blood cells, white blood cells, and crystals in the urine.
If your patient presents with these findings, you should suspect nephrolithiasis.
Next, order a non-contrast helical CT scan of the abdomen and pelvis to check for stone presence. If there’s no stones on the scan, then consider alternative diagnoses. Alternatively, if the CT scan reveals a stone, that confirms the diagnosis of nephrolithiasis.
The next step is pain management – find out here: osms.it/decision-tree-branch-nephrolithiasis-yt
Try Osmosis from Elsevier for free: osms.it/free-trial-nov24-yt
701 - 2
Happy #NursePractitionerWeek to all current, future, and retired NPs! Thank you for the care you pour into keeping our communities healthy and safe. All vital signs point to yes, you're the lifeline of healthcare systems everywhere! 🫀✨
Tag an NP in your life in the comments below to show your appreciation! And send them extra love today with a sweet Spread Joy eCard: osms.it/sj-np-week-nov24-yt
345 - 1
Clot on, clot off... today's #PhysiologyFeature is all about clot retraction!
Anticoagulation, or clot retraction, is a process that occurs with primary and secondary hemostasis. Anticoagulation is critical, as it prevents the clot from getting too big.
Thrombin plays a major role in coagulation, so naturally, it's the main target of two proteins that help with anticoagulation: protein C and antithrombin III.
Protein C is a circulating plasma protein produced in the liver along with a cofactor called protein S. Both proteins C and S interact with a protein called thrombomodulin, which is on the surface of intact endothelial cells, which line our blood vessels.
In an existing clot, when there’s a lot of thrombin around a damaged blood vessel, excess thrombin binds to thrombomodulin, and it can no longer participate in the coagulation cascade. Furthermore, the thrombin-thrombomodulin bind to protein C and S and create a complex that inactivates active factors V and VIII.
The other important protein for anticoagulation is antithrombin III, also known as just antithrombin. Antithrombin is also made by the liver. It inhibits thrombin and factor X. Antithrombin also inhibits factors VII, IX, XI, and XII--although with much less affinity.
Heparin actually binds to antithrombin and increases its affinity for target proteins, thus increasing its anticoagulant effects. So, when patient are given heparin, the balance between coagulation and anticoagulation tips in favor of anticoagulation.
Learn more about the anticoagulation: osms.it/physiology-anticoagulation-yt
Try Osmosis from Elsevier for free: osms.it/free-trial-nov24-yt
810 - 0
Osmosis.org is a leading medical & health education platform with an audience of over 6 million current & future clinicians & caregivers. Our vision: Everyone who cares for someone will learn by Osmosis!
Our YouTube channel features general consumer health videos to educate the public about important medical concepts. The Osmosis.org learning platform features more in-depth basic and clinical sciences videos for health professionals and students, hundreds of decision making trees, thousands of board-style practice questions and flashcards, and advanced features like quiz builders, playlists, collaborative tools, mobile app, and more.
© 2023 Elsevier. All rights reserved.